News Celgene files AML pill after fast-track trial The FDA has accepted Celgene’s filing for enasidenib.
News Novartis drug gets fast US review in AML Midostaurin also under review in rare disease systemic mastocytosis
Partner Content Partner Content Positive PIII results for VYXEOS revealed at ASCO Building on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the Phase III (PIII) findings for its combination therapy VYXEOS (cytarabine and daun
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
